HSBC Downgrades AstraZeneca Following Key Trial Failure

HSBC downgraded its rating for AstraZeneca to 'hold' from 'buy', citing a failed phase III trial as the key reason. The bank reduced its target price and expressed concerns over future revenue growth, impacting investor confidence.

By Proactive Mon, July 13, 2026 at 3:06 PM GMT+3 2 min read · Yahoo Finance · July 13, 2026, 12:06 UTC

HSBC Downgrades AstraZeneca Following Key Trial Failure

Tickers: $AZN $HSBC

Topics: Clinical Trials Pharmaceuticals Stock Downgrades

Read the full article at Yahoo Finance

More World news

Canadian Tire Announces Quarterly Dividend of CAD 1.825 Per Share Seeking Alpha · November 12, 2026, 13:58 UTC
Chicago Atlantic BDC Announces $0.34 Per Share Quarterly Dividend Seeking Alpha · November 12, 2026, 13:59 UTC
William Blair Upgrades AMD to Outperform Amid Leadership Crisis at Nvidia CNBC · November 12, 2026, 13:56 UTC
HawkEye 360 Secures $135 Million in New Global Contracts Seeking Alpha · November 12, 2026, 13:55 UTC
Databento Secures $100 Million Series C Funding at $1.1 Billion Valuation PR Newswire · November 12, 2026, 13:57 UTC
Annex Brands Announces Franchise Renewal for Postal Connections in Fort Mohave, Arizona PR Newswire · November 12, 2026, 13:58 UTC
Nvidia CEO Jensen Huang Resigns Following Personal Scandals and Espionage Allegations The Verge · November 12, 2026, 13:53 UTC
AMD and PsiQuantum Partner to Develop Fault-Tolerant Quantum Computing Infrastructure Seeking Alpha · November 12, 2026, 13:44 UTC
Nvidia CEO Jensen Huang Resigns; CFO Colette Kress Appointed Interim CEO Seeking Alpha · November 12, 2026, 13:50 UTC
Aktis Oncology Reports Q3 Revenue Growth and Significant Increase in Cash Reserves Seeking Alpha · November 12, 2026, 13:50 UTC